Clinical Trial Update: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ropeginterferon alfa-2b (P1101) to anagrelide in essential thrombocythemia patients with hydroxyurea resistance or intolerance; study st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia

Drugs mentioned

• ANAGRELIDE (Anagrelide)
• Ropeginterferon alfa-2b (P1101) (ropeginterferon alfa-2b)

Snippet

Sponsor: PharmaEssentia | Conditions: Essential Thrombocythemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING